Dynamics of India's Life Sciences Outsourcing Industry - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Dynamics of India's Life Sciences Outsourcing Industry
The tightening of intellectual property rights in India under GATT/TRIPS was a crucial inflection point for pharmaceutical outsourcing in India.

Pharmaceutical Technology

Looking forward

From the author's experience, most pharmaceutical and biotechnology companies came to India for cost savings. All of them stayed for India's quality in scientific talent and infrastructure. And today, most of them are investing in the country for growth and productivity. Some Indian executives have the necessary wherewithal, will, stamina, and long-term commitment to serve the industry and to create value for all involved. As the life sciences industry metamorphoses into its next phase, executives at global biotechnology and pharmaceutical companies need to think of India in a more open-minded, comprehensive, and collaborative manner to fully exploit its potential.

Nailesh A. Bhatt is managing director at Proximare Inc., 100 Overlook Center, Princeton, NJ 08540, tel. 732. 297.7007,


1. Global Business Policy Council, "FDI Confidence Index," (A.T. Kearney, Alexandria, VA, 2005).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here